ArticleBMC ophthalmology2025
Predictive biomarkers for the prognosis of phacoemulsification and posterior chamber intraocular lens implantation in Fuchs endothelial corneal dystrophy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the clinical outcomes and related risk factors following phacoemulsification and posterior chamber intraocular lens implantation (PE & PCL) in East Asian patients with Fuchs endothelial corneal dystrophy (FECD).
methodsOne hundred eighty eyes of 112 FECD patients who underwent PE & PCL at a tertiary hospital in Korea were included. Demographic and ocular biometric characteristics including best-corrected visual acuity (BCVA), central corneal thickness (CCT), and endothelial cell density (ECD) were collected. Risk factors were analyzed for (1) Descemet membrane endothelial keratoplasty (DMEK) requirement and (2) postoperative BCVA < 0.5, using univariate and multivariate regression analyses and receiver operating characteristic curves.
resultsMean LogMAR BCVA improved from 0.51 to 0.20, CCT increased by 2.6% from baseline, and ECD decreased by 14.6% (all P < 0.05). Ten eyes (5.6%) underwent subsequent DMEK within three months. Baseline CCT was a risk factor for the need for DMEK (odds ratio 1.58, P < 0.05) with a cutoff value of 620 μm, achieving 100% sensitivity and 91% specificity. Baseline BCVA, CCT, and ECD predicted limited postoperative BCVA (all P < 0.05), with cutoff values of 0.35 logMAR (91% sensitivity and 59% specificity), 584 μm (57% sensitivity and 82% specificity), and 1244 cells/mm
conclusionsIn our cohort of Korean FECD eyes that underwent routine PE & PCL, progression to DMEK in the early postoperative period was relatively low. Baseline CCT values provide strong predictive power for both the necessity of DMEK and the likelihood of visual improvement after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.